Edition:
India

Cascadian Therapeutics Inc (CASC.OQ)

CASC.OQ on NASDAQ Stock Exchange Global Select Market

4.27USD
19 Jan 2018
Change (% chg)

$0.10 (+2.40%)
Prev Close
$4.17
Open
$4.17
Day's High
$4.38
Day's Low
$4.17
Volume
64,987
Avg. Vol
88,259
52-wk High
$4.97
52-wk Low
$3.20

Chart for

About

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth... (more)

Overall

Beta: 2.37
Market Cap(Mil.): $221.93
Shares Outstanding(Mil.): 50.55
Dividend: --
Yield (%): --

Financials

BRIEF-Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver From The European Medicines Agency

* CASCADIAN THERAPEUTICS RECEIVES PEDIATRIC INVESTIGATION PLAN WAIVER FROM THE EUROPEAN MEDICINES AGENCY Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

02 Jan 2018

BRIEF-Cascadian Therapeutics reports Q3 loss per share $0.28

* Cascadian Therapeutics reports third quarter 2017 financial results

09 Nov 2017

BRIEF-Cascadian Therapeutics announces FDA orphan drug designation granted to Tucatinib for the treatment of HER2 colorectal cancer

* Cascadian Therapeutics announces FDA orphan drug designation granted to tucatinib for the treatment of HER2+ metastatic colorectal cancer Source text for Eikon: Further company coverage:

27 Sep 2017

BRIEF-Cascadian Therapeutics Q2 loss per share $0.30

* Cascadian Therapeutics reports second quarter 2017 financial results

09 Aug 2017

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF234.50 +1.30
Roche Holding Ltd. (RO.S) CHF237.80 +1.00
GlaxoSmithKline plc (GSK.L) 1,358.00 +4.80
Eli Lilly and Co (LLY.N) $85.49 -0.33
Transgene SA (TRNG.PA) €3.03 +0.01
Puma Biotechnology Inc (PBYI.OQ) $91.60 +3.35

Earnings vs. Estimates